Magellan Health, Inc. (NASDAQ: MGLN) today announced financial
results for the first quarter ended March 31, 2019, as summarized
below:
Three Months Ended March
31 (In millions, except per share amounts)
2019
2018
Chg
Net revenue $ 1,739.5 $ 1,805.1 -3.6 % Net income $ 0.4 $ 11.5
-96.2 % Segment profit [1] $ 45.6 $ 55.6 -18.0 % Adjusted net
income [1] $ 9.6 $ 20.8 -54.0 % Earnings per share $ 0.02 $ 0.45
-95.6 % Adjusted earnings per share [1] $ 0.40 $ 0.81 -50.6 %
[1] Refer to the Basis of Presentation for a discussion of
non-GAAP financial measures.
For First Quarter:
- Net revenue decreased 3.6 percent over
the first quarter of 2018 to $1.7 billion.
- Net income decreased 96.2 percent over
the first quarter of 2018 to $0.4 million.
- Segment profit decreased 18 percent
over the first quarter of 2018 to $45.6 million.
- Adjusted net income decreased 54
percent over the first quarter of 2018 to $9.6 million.
- Unrestricted cash and investments were
$194.9 million as of March 31, 2019. Approximately $88.4 million of
the unrestricted cash and investments at March 31, 2019 is related
to excess capital and undistributed earnings held at regulated
entities.
- The Company is affirming its full year
2019 earnings guidance, but modestly lowering revenue guidance to a
range of $7.0 to $7.2 billion.
“Overall, our Healthcare results were solid, and our Pharmacy
results for the quarter were impacted by some unfavorable
out-of-period and timing items related to network costs,” said
Barry M. Smith, chairman and chief executive officer of Magellan
Health. “I’m pleased with the actions we completed during the first
quarter in 2019 which represent significant progress towards
achieving our margin improvement plan. We’re seeing the benefits of
the strong leadership we’ve put in place over the last six months,
particularly in our MCC segment. We have a clear path to achieve
our full year earnings guidance, and I’m confident in the team and
our ability to execute.”
Net Revenue
Net revenue for the first quarter ended March 31, 2019, was $1.7
billion, a decrease of 3.6 percent over the same period in 2018.
This decrease was mainly driven by our Magellan Complete Care (MCC)
of Florida and Medicare Part D footprint reductions as well as the
previously discussed PBM healthplan contract loss due to an
acquisition, partially offset by growth in MCC of Virginia and new
PBM employer business.
Segment Profit
Segment profit was $45.6 million for the first quarter, compared
to $55.6 million in the prior year quarter.
- Healthcare segment profit was $45.0
million, which represents a decrease of $0.9 million versus the
first quarter of 2018. This decrease was mainly driven by the MCC
of Florida footprint reduction and lower margins in New York,
partially offset by margin improvements in Virginia.
- Pharmacy Management segment profit was
$8.3 million, which was a decrease of $7.2 million from the first
quarter of 2018. This year-over-year decrease was primarily driven
by specialty formulary management contract losses, non-recurring
items, and lower PBM membership.
- Corporate costs inclusive of
eliminations, but excluding stock compensation expense, totaled
$7.7 million, compared to $5.8 million in the prior year’s quarter.
This change was largely due to lower discretionary benefit expenses
in the prior year quarter.
Cash Flow & Balance Sheet
Cash flow from operations for the quarter ended March 31, 2019,
was $35.4 million, as compared to $81.0 million in the first
quarter of 2018. The prior year’s quarterly cash flow was unusually
high due to the favorable timing of working capital.
As of March 31, 2019, the Company’s unrestricted cash and
investments totaled $194.9 million, which represents an increase of
$64.5 million from the balance at December 31, 2018, primarily due
to the collection of certain outstanding receivables. Approximately
$88.4 million of the unrestricted cash and investments at March 31,
2019 is related to excess capital and undistributed earnings held
at regulated entities.
Restricted cash and investments at March 31, 2019, of $468.8
million reflect a decrease of $58.8 million from the balance at
December 31, 2018 due to timing. During the quarter the Company
repurchased approximately 61 thousand shares for $3.7 million.
“The fundamentals of our business remain strong, and we are
focused on continuing to execute our margin improvement plan for
the balance of the year,” said Jonathan N. Rubin, chief financial
officer of Magellan Health. “I remain confident in our long-term
growth strategy.”
Outlook
The Company is affirming its 2019 earnings guidance ranges, but
modestly lowering the revenue guidance to a range of $7.0 to $7.2
billion.
2019 Guidance (In millions,
except per share amounts)
Low
High
Net revenue $ 7,000.0 $ 7,200.0 Income before income taxes $ 75.0 $
117.0 Net income $ 52.0 $ 79.0 Segment Profit[1] $ 270.0 $ 290.0
Adjusted net income[1] $ 90.0 $ 114.0 Earnings per share[2] $ 2.14
$ 3.25 Adjusted earnings per share[1][2] $ 3.70 $ 4.69 [1]
Refer to the Basis of Presentation for a discussion of non-GAAP
financial measures. [2] 2019 EPS and Adjusted EPS guidance includes
share repurchases and option exercises through the close of
business April 26, 2019, but excludes the impact of any potential
future activity.
Earnings Conference Call
Management will discuss the Company’s first quarter results on a
conference call scheduled for Thursday, May 2, 2019 at 7:30
a.m. Eastern. To participate in the conference call, dial
1-800-857-1812 and use passcode “1st Quarter 2019 Earnings Call”
approximately 10 minutes before the start of the call. The
conference call will also be available live via webcast at
Magellan's investor relations page at IR.MagellanHealth.com. A
telephonic replay will be available shortly after the conclusion of
the call through June 2, 2019. This replay may be accessed by
dialing 1-800-324-4693 (Domestic) or 1-203-369-3245
(International). A replay of the webcast will also be available at
the site listed above for 30 days, beginning approximately two
hours after its conclusion.
Basis of Presentation
In addition to results determined under Generally Accepted
Accounting Principles (GAAP), Magellan provides certain non-GAAP
financial measures that management believes are useful in assessing
the Company’s performance. Following is a description of these
important non-GAAP measures.
Segment profit is equal to net revenue less the sum of cost of
care, cost of goods sold, direct service costs and other operating
expenses, and includes income from unconsolidated subsidiaries, but
excludes segment profit or loss from non-controlling interests held
by other parties, stock compensation expense, special charges or
benefits, as well as changes in the fair value of contingent
consideration recorded in relation to acquisitions.
Adjusted net income and adjusted earnings per share reflect
certain adjustments made for acquisitions completed after
January 1, 2013, to exclude non-cash stock compensation
expense resulting from restricted stock purchases by sellers,
changes in the fair value of contingent consideration, amortization
of identified acquisition intangibles, as well as impairment of
identified acquisition intangibles.
Included in the tables issued with this press release are the
reconciliations from GAAP measures to the corresponding non-GAAP
measures.
About Magellan Health: Magellan Health, Inc., a Fortune
500 company, is a leader in managing the fastest growing, most
complex areas of health, including special populations, complete
pharmacy benefits and other specialty areas of healthcare. Magellan
supports innovative ways of accessing better health through
technology, while remaining focused on the critical personal
relationships that are necessary to achieve a healthy, vibrant
life. Magellan's customers include health plans and other managed
care organizations, employers, labor unions, various military and
governmental agencies and third-party administrators. For more
information, visit MagellanHealth.com.
Forward-Looking Statements
This release is intended to be disclosure through methods
reasonably designed to provide broad, non-exclusionary distribution
to the public in compliance with the Securities and Exchange
Commission’s Fair Disclosure Regulation. This release contains
forward-looking statements within the meaning of the Securities
Exchange Act of 1934 and the Securities Act of 1933, as amended,
which involve a number of risks and uncertainties, many of which
are out of our control. All statements, other than statements of
historical information provided herein, may be deemed to be
forward-looking statements including, without limitation,
statements regarding 2019 guidance for net revenue, income before
income taxes, net income, earnings per share, segment profit,
adjusted net income, adjusted earnings per share; and multi-year
margin improvement plan, growth opportunities, business
environment, long term opportunities and strategy. These statements
are based on management’s analysis, judgment, belief and
expectation only as of the date hereof, and are subject to
uncertainty and changes in circumstances. Without limiting the
foregoing, the words “believes,” “anticipates,” “plans,” “expects,”
“may,” “should,” “could,” “estimate,” “intend” and other similar
expressions are intended to identify forward-looking statements.
Actual results could differ materially due to, among other things,
the possible election of certain of the Company’s customers to
manage the healthcare services of their members directly; changes
in rates paid to and/or by the Company by customers and/or
providers; higher utilization of healthcare services by the
Company’s risk members; delays, higher costs or inability to
implement new business or other Company initiatives; the impact of
changes in the contracting model for Medicaid contracts;
termination or non-renewal of customer contracts; the impact of new
or amended laws or regulations; governmental inquiries; litigation;
competition; operational issues; healthcare reform; and general
business conditions. Additional factors that could cause actual
results to differ materially from those reflected in the
forward-looking statements include, but are not limited to, the
risks discussed in the “Risk Factors” section included within the
Company’s Annual Report on Form 10-K for the year ended December
31, 2018, filed with the Securities and Exchange Commission on
February 28, 2019, and the Company’s subsequent Quarterly Reports
on Form 10-Q filed during 2019. Readers are cautioned not to place
undue reliance on these forward-looking statements. The Company
undertakes no obligation to publicly revise these forward-looking
statements to reflect events or circumstances that arise after the
date of this release. Segment profit, adjusted net income, and
adjusted EPS information referred to herein may be considered a
non-GAAP financial measure. Further information regarding these
measures, including the reasons management considers this
information useful to investors, are included in the Company’s most
recent Annual Report on Form 10-K and on subsequent Form 10-Qs.
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS (In thousands)
December 31,
2018 March 31, 2019 (unaudited) ASSETS
Current Assets: Cash and cash equivalents $ 272,308 $
233,401 Accounts receivable, net 756,059 779,863 Short-term
investments 382,582 412,732 Pharmaceutical inventory 40,818 47,151
Other current assets 95,400 99,908
Total Current Assets 1,547,167 1,573,055 Property and equipment,
net 150,748 149,520 Long-term investments 3,161 17,639 Deferred
income taxes 3,411 3,581 Other long-term assets 24,530 90,997
Goodwill 1,018,156 1,018,156 Other intangible assets, net
231,883 218,209 Total Assets $ 2,979,056
$ 3,071,157
LIABILITIES AND STOCKHOLDERS'
EQUITY Current Liabilities: Accounts payable $ 72,077 $
75,041 Accrued liabilities 231,356 260,954 Short-term contingent
consideration 8,000 - Medical claims payable 393,547 399,055 Other
medical liabilities 169,639 183,802 Current debt, finance lease and
deferred financing obligations 24,274 25,006
Total Current Liabilities 898,893 943,858 Long-term debt,
finance lease and deferred financing obligations 728,608 722,925
Deferred income taxes 11,167 11,105 Tax contingencies 16,478 16,589
Long-term contingent consideration 2,124 2,268 Deferred credits and
other long-term liabilities 36,483 81,022
Total Liabilities 1,693,753 1,777,767
Stockholders’ Equity: Ordinary common stock 535 537
Additional paid-in capital 1,326,645 1,337,849 Retained earnings
1,419,449 1,419,735 Accumulated other comprehensive loss (324 ) (4
) Ordinary common stock in treasury, at cost (1,461,002 )
(1,464,727 ) Total Stockholders’ Equity 1,285,303
1,293,390 Total Liabilities and Stockholders’
Equity $ 2,979,056 $ 3,071,157
MAGELLAN HEALTH, INC. AND SUBSIDIARIES CONSOLIDATED
STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) (In
thousands, except per share amounts)
Three Months Ended March 31,
2018 2019 Net revenue: Managed care and other $
1,219,763 $ 1,223,979 PBM 585,314 515,510
Total net revenue 1,805,077 1,739,489
Costs and expenses: Cost of care 928,661 941,961 Cost
of goods sold 559,665 489,793 Direct service costs and other
operating expenses (1)(2) 269,077 271,924 Depreciation and
amortization 30,407 30,708 Interest expense 8,366 9,107 Interest
and other income (2,476 ) (4,974 ) Total costs and
expenses 1,793,700 1,738,519 Income
before income taxes 11,377 970 (Benefit) provision for income taxes
(75 ) 539 Net income $ 11,452 $ 431
Weighted average number of common shares outstanding
— basic 24,349 23,946 Weighted average number of common shares
outstanding — diluted 25,612 24,213 Net income per common
share — basic $ 0.47 $ 0.02 Net income per common share — diluted $
0.45 $ 0.02 Net income $ 11,452 $ 431 Other comprehensive
income: Unrealized (losses) gains on available-for-sale securities
(3) (319 ) 320 Comprehensive income $ 11,133
$ 751 (1) Includes stock compensation expense
of $7,646 and $9,607 for the three months ended March 31, 2018 and
2019, respectively. (2) Includes changes in fair value of
contingent consideration of $233 and $144 for the three months
ended March 31, 2018 and 2019, respectively. (3) Net of
income tax (benefit) provision of ($101) and $100 for the three
months ended March 31, 2018 and 2019, respectively.
MAGELLAN HEALTH, INC. AND SUBSIDIARIES CONSOLIDATED
STATEMENTS OF CASH FLOWS (Unaudited) (In
thousands) Three Months
Ended March 31, 2018 2019 Cash flows
from operating activities: Net income $ 11,452 $ 431
Adjustments to reconcile net income to net cash from operating
activities: Depreciation and amortization 30,407 30,708 Non-cash
interest expense 307 326 Non-cash stock compensation expense 7,646
9,607 Non-cash income tax provision (benefit) 62 (250 ) Non-cash
amortization on investments 809 (192 ) Changes in assets and
liabilities, net of effects from acquisitions of businesses:
Accounts receivable, net (87,178 ) (23,804 ) Pharmaceutical
inventory 3,067 (6,333 ) Other assets (37,914 ) (10,835 ) Accounts
payable and accrued liabilities 26,529 20,399 Medical claims
payable and other medical liabilities 107,569 19,671 Contingent
consideration 233 (1,609 ) Tax contingencies 448 83 Deferred
credits and other long-term liabilities 17,685 (2,889 ) Other
(90 ) 111 Net cash provided by operating
activities 81,032 35,424
Cash
flows from investing activities: Capital expenditures (19,502 )
(12,642 ) Acquisitions and investments in businesses, net of cash
acquired - (320 ) Purchases of investments (142,886 ) (172,766 )
Proceeds from maturities and sales of investments 118,999
128,748 Net cash used in investing activities
(43,389 ) (56,980 )
Cash flows from
financing activities: Payments to acquire treasury stock -
(4,124 ) Proceeds from exercise of stock options 16,897 2,045
Payments on debt, finance lease and deferred financing obligations
(55,895 ) (7,323 ) Payments on contingent consideration - (6,247 )
Other (3,051 ) (1,702 ) Net cash used in financing
activities (42,049 ) (17,351 ) Net decrease in
cash and cash equivalents (4,406 ) (38,907 ) Cash and cash
equivalents at beginning of period 398,732
272,308 Cash and cash equivalents at end of period $ 394,326
$ 233,401
MAGELLAN HEALTH, INC. AND
SUBSIDIARIES CONSOLIDATED OPERATING RESULTS BY BUSINESS
SEGMENT (Unaudited) (In thousands)
Three Months Ended March 31,
2018 2019
Healthcare
Managed care and other revenue $ 1,157,601 $ 1,164,253 Cost of care
(928,661 ) (941,961 ) Direct service costs and other (186,246 )
(179,190 ) Stock compensation expense (1) 2,950 1,750 Changes in
fair value of contingent consideration (1) 233
144 Healthcare segment profit 45,877 44,996
Pharmacy
Management
Managed care and other revenue 62,307 59,895 PBM revenue 632,198
556,565 Cost of goods sold (604,913 ) (530,207 ) Direct service
costs and other (75,586 ) (79,635 ) Stock compensation expense (1)
1,485 1,672 Pharmacy Management segment
profit 15,491 8,290
Corporate and
Elimination (2)
Managed care and other revenue (145 ) (169 ) PBM revenue (46,884 )
(41,055 ) Cost of goods sold 45,248 40,414 Direct service costs and
other (7,245 ) (13,099 ) Stock compensation expense (1)
3,211 6,185 Corporate and Elimination (5,815 )
(7,724 )
Consolidated
Managed care and other revenue 1,219,763 1,223,979 PBM revenue
585,314 515,510 Cost of care (928,661 ) (941,961 ) Cost of goods
sold (559,665 ) (489,793 ) Direct service costs and other (269,077
) (271,924 ) Stock compensation expense (1) 7,646 9,607 Changes in
fair value of contingent consideration (1) 233
144 Consolidated segment profit $ 55,553 $ 45,562
Reconciliation of income before income
taxes to segment profit: Income before income taxes $ 11,377 $
970 Stock compensation expense 7,646 9,607 Changes in fair value of
contingent consideration 233 144 Depreciation and amortization
30,407 30,708 Interest expense 8,366 9,107 Interest and other
income (2,476 ) (4,974 ) Segment profit $ 55,553
$ 45,562 (1) Stock compensation expense,
changes in the fair value of contingent consideration recorded in
relation to acquisitions and impairment of intangible assets are
included in direct service costs and other operating expenses;
however, these amounts are excluded from the computation of segment
profit. (2) Healthcare subcontracts with Pharmacy Management
to provide pharmacy benefits management services for certain of
Healthcare’s customers. In addition, Pharmacy Management provides
pharmacy benefits management for the Company’s employees covered
under its medical plan. As such, revenue, cost of goods sold and
direct service costs and other related to these arrangements are
eliminated.
MAGELLAN HEALTH, INC. AND
SUBSIDIARIES NON-GAAP MEASURES (Unaudited) (In
thousands, except per share amounts)
Three Months Ended March 31,
2018 2019 Net income $ 11,452 $ 431 Adjusted
for acquisitions starting in 2013 Stock compensation expense 262 -
Changes in fair value of contingent consideration 233 144
Amortization of acquired intangibles 11,871 12,272 Tax impact
(3,013 ) (3,282 ) Adjusted net income $ 20,805
$ 9,565 Net income per common share — diluted
$ 0.45 $ 0.02 Adjusted for acquisitions starting in 2013 Stock
compensation expense 0.01 - Changes in fair value of contingent
consideration 0.01 0.01 Amortization of acquired intangibles 0.46
0.50 Tax impact (0.12 ) (0.13 ) Adjusted earnings per
share $ 0.81 $ 0.40
MAGELLAN HEALTH,
INC. AND SUBSIDIARIES FISCAL 2019 GUIDANCE
RECONCILIATION OF GAAP TO NON-GAAP MEASURES (In millions,
except per share amounts)
Low High Net income attributable
to Magellan $ 52.0 $ 79.0 Adjusted for acquisitions starting in
2013 Stock compensation expense - - Changes in fair value of
contingent consideration - - Amortization of acquired intangibles
52.0 47.0 Tax impact (14.0 ) (12.0 ) Adjusted net
income $ 90.0 $ 114.0 Net income
per common share attributable to Magellan —Diluted $ 2.14 $ 3.25
Adjusted for acquisitions starting in 2013 Stock compensation
expense - - Changes in fair value of contingent consideration - -
Amortization of acquired intangibles 2.14 1.93 Tax impact
(0.58 ) (0.49 ) Adjusted earnings per share $ 3.70 $
4.69 Reconciliation of income before
income taxes to segment profit: Income before income taxes $ 75.0 $
117.0 Stock compensation expense 33.0 29.0 Changes in fair value of
contingent consideration - - Depreciation and amortization 136.0
126.0 Interest expense 38.0 34.0 Interest income (12.0 )
(16.0 ) Segment profit $ 270.0 $ 290.0
(MGLN-GEN)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190502005235/en/
Media Contact: Lilly Ackley, ackleyl@magellanhealth.com,
(860) 507-1923Investor Contact: Joe Bogdan,
jbogdan@magellanhealth.com, (860) 507-1910
Magellan Health (NASDAQ:MGLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Magellan Health (NASDAQ:MGLN)
Historical Stock Chart
From Apr 2023 to Apr 2024